News Biogen buys CNS delivery specialist Alcyone Therapeutics Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.
News Biogen races into phase 3 with Spinraza follow-up Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.
News SMA treatment with Evrysdi 'could start prenatally' Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.
News US/EU regulators start review of Biogen's high-dose Spinraza Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
News Scholar Rock preps filings after SMA antibody clears trial Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory fi
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.